<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7418</journal-id>
<journal-title><![CDATA[Revista Colombiana de Ciencias Químico - Farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. cienc. quim. farm.]]></abbrev-journal-title>
<issn>0034-7418</issn>
<publisher>
<publisher-name><![CDATA[Departamento de Farmácia, Facultad de Ciencias, Universidade Nacional da Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74182022000100089</article-id>
<article-id pub-id-type="doi">10.15446/rcciquifa.v51n1.102676</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Hipersensibilidad al trimetoprim + sulfametoxazol en un paciente con osteomielitis en esquema de desensibilización]]></article-title>
<article-title xml:lang="en"><![CDATA[Hypersensitivity to trimethoprim + sulfamethoxazole in an Osteomyelitis desensitization-dosing schedule patient]]></article-title>
<article-title xml:lang="pt"><![CDATA[Hipersensibilidade ao trimetoprim + sulfametoxazol em paciente com esquema posológico de dessensibilização da osteomielite]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arroyo Monterroza]]></surname>
<given-names><![CDATA[Dadier Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López García]]></surname>
<given-names><![CDATA[Raul Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinto Camacho]]></surname>
<given-names><![CDATA[Lisbeth Katlin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Atlántico  ]]></institution>
<addr-line><![CDATA[Puerto Colombia Atlántico]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad del Atlántico  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad del Atlántico Facultad de Química y Farmacia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<volume>51</volume>
<numero>1</numero>
<fpage>89</fpage>
<lpage>99</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74182022000100089&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74182022000100089&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74182022000100089&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: La osteomielitis es una inflamación del tejido óseo, la cual puede ser causada por un agente infeccioso de tipo Gram positivo como Gram negativo, generalmente ocasionado por Staphylococcus aureus; esta infección usualmente es tratada con trimetoprim + sulfametoxazol, desafortunadamente durante el tratamiento pueden aparecer reacciones adversas a medicamentos de tipo alérgicas, lo que implicaría un cambio de antibiótico o someter al paciente a esquema de desensibilización.  Objetivo: Reportar el caso de un paciente que fue sometido a dicho esquema, empleando la vía intravenosa.  Resultados: Paciente masculino de 14 años de edad ingresó a la institución con osteomielits de tibia derecha en su posoperatorio de osteosintesis realizado dos meses antes. Se decidió iniciar tratamiento con TMP-SMX 300 mg intravenoso (IV) cada 12 horas. Se informó al paciente y ya que era menor de edad, a su familiar a cargo sobre la importancia del procedimiento, posibles riesgos y beneficios mediante consentimiento informado por escrito. El paciente presentó una erupción cutánea acompañada de prurito en el pecho y espalda, lo cual fue tratado y solucionado, por consiguiente se dispuso a someter al paciente al esquema para su desensibilización el cual fue realizado empleando el medicamento en solución inyectable (trimetoprim + sulfametoxazol 400 mg + 80 mg/5 mL) para dar continuidad a su tratamiento, además el paciente fue monitorizado y no se le administró tratamiento con antihistamínicos o corticoides para así evitar una respuesta errónea o resultados falsos/positivos durante el procedimiento.  Conclusión: El paciente fue desensibilizado con éxito para continuar con su tratamiento farmacológico. Este caso reportado puede contribuir a modificar los esquemas de desensibilización actuales, el esquema de desensibilización es una herramienta muy útil para continuar el tratamiento farmacológico en pacientes con hipersensibilidad al TMP/SMX, sin necesidad de optar por otras alternativas terapéuticas que podrían ser menos eficaces para el control de la infección.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Introduction: Osteomyelitis is an inflammation of the bone tissue, which can be caused by a Gram-positive or Gram-negative infectious agent, generally caused by Staphylococcus aureus. This infection is usually treated with trimethoprim + sulfamethoxazole. Unfortunately, adverse drug reactions of the allergic type may appear during treatment, which would imply a change of antibiotic or subject the patient to a desensitization scheme.  Objective: To report the case of a patient who underwent this scheme, using the intravenous route.  Results: A 14-year-old male patient was admitted to the institution with osteomyelitis of the right tibia in his postoperative period of osteosynthesis performed two months earlier. It was decided to start treatment with TMP-SMX 300 mg intravenously (IV) every 12 hours. The patient and, since he was a minor, his dependent relative were informed about the importance of the procedure, possible risks and benefits through written informed consent. The patient presented a skin rash accompanied by itching on the chest and back. which was treated and resolved, therefore, the patient was submitted to the scheme for his desensitization, which was carried out using the medicine in injectable solution (trimethoprim + sulfamethoxazole 400 mg + 80 mg/5 mL) to continue his treatment, In addition, the patient was monitored and treatment with antihistamines or corticosteroids was not administered in order to avoid an erroneous response or false/positive results during the procedure.  Conclusion: The patient was successfully desensitized to continue with his pharmacological treatment. This reported case can contribute to modify the current desensitization schemes; the desensitization scheme is a very useful tool to continue pharmacological treatment in patients with hypersensitivity to TMP/SMX, without the need to opt for other therapeutic alternatives that could be less effective for infection control.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução: A osteomielite é uma inflamação do tecido ósseo, que pode ser causada por um agente infeccioso Gram-positivo ou Gram-negativo, geralmente causado por Staphylococcus aureus; essa infecção geralmente é tratada com trimetoprima + sulfametoxazol, mas infelizmente, durante o tratamento, podem surgir reações adversas medicamentosas do tipo alérgico, o que implicaria na troca de antibiótico ou submeter o paciente a um esquema de dessensibilização.  Objetivo: Relatar o caso de um paciente submetido a esse esquema, pela via intravenosa.  Resultados: Um paciente do sexo masculino de 14 anos foi admitido na instituição com osteomielite da tíbia direita em pós-operatório de osteossíntese realizada há dois meses. Optou-se por iniciar o tratamento com TMP-SMX 300 mg por via intravenosa (IV) a cada 12 horas. O paciente e, por ser menor de idade, seu familiar dependente foram informados sobre a importância do procedimento, possíveis riscos e benefícios por meio do termo de consentimento livre e esclarecido. O paciente apresentou erupção cutânea acompanhada de coceira no tórax e nas costas, que foi tratado e resolvido, portanto, o paciente foi submetido ao esquema para sua dessensibilização, que foi realizada utilizando o medicamento em solução injetável (trimetoprim + sulfa-metoxazol 400 mg + 80 mg/5 mL) para continuar seu tratamento. o paciente foi monitorado e não foi administrado tratamento com anti-histamínicos ou corticos-teróides para evitar resposta errônea ou resultados falsos/positivos durante o procedimento.  Conclusão: O paciente foi dessensibilizado com sucesso para continuar com seu tratamento farmacológico. Este caso relatado pode contribuir para modificar os esquemas de dessensibilização atuais, o esquema de dessensibilização é uma ferramenta muito útil para continuar o tratamento farmacológico em pacientes com hipersensibilidade ao TMP/SMX, sem a necessidade de optar por outras alternativas terapêuticas que poderiam ser menos eficazes para o controle de infecção.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Osteomielitis]]></kwd>
<kwd lng="es"><![CDATA[hipersensibilidad]]></kwd>
<kwd lng="es"><![CDATA[trimetoprim +sulfametoxazol]]></kwd>
<kwd lng="es"><![CDATA[desensibilización]]></kwd>
<kwd lng="en"><![CDATA[Osteomyelitis]]></kwd>
<kwd lng="en"><![CDATA[hypersensitivity]]></kwd>
<kwd lng="en"><![CDATA[trimethoprim + sulfamethoxazole]]></kwd>
<kwd lng="en"><![CDATA[desensitization]]></kwd>
<kwd lng="pt"><![CDATA[Osteomielite]]></kwd>
<kwd lng="pt"><![CDATA[hipersensibilidade]]></kwd>
<kwd lng="pt"><![CDATA[trimetoprima + sulfametoxazol]]></kwd>
<kwd lng="pt"><![CDATA[dessensibilização]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[A.L.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[P.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[V.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Cimerman]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Savio]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(Directrices Panamericanas para el tratamiento de las osteomielitis e infecciones de tejidos blandos Group), Recommendations for the treatment of osteomielitis]]></article-title>
<source><![CDATA[Braz. J. Infect. Dis]]></source>
<year>2014</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>526-34</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trueta]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The three types of acute haematogenous osteomyelitis: a clinical and vascular study]]></article-title>
<source><![CDATA[J. Bone Joint. Surg]]></source>
<year>1959</year>
<volume>41</volume>
<page-range>671-80</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mruk]]></surname>
<given-names><![CDATA[A.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Record]]></surname>
<given-names><![CDATA[K.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antimicrobial options in the treatment of adult staphylococcal bone and joint infections in an era of drug shortages]]></article-title>
<source><![CDATA[Orthopedics]]></source>
<year>2012</year>
<volume>35</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>401-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prieto-Pérez]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Tanoira]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Petkova-Saiz]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Jorge]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Rodriguez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Alvarez]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Polo-Sabau]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteomyelitis: A descriptive study]]></article-title>
<source><![CDATA[Clin. Orthop. Surg]]></source>
<year>2014</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>20-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Knowles]]></surname>
<given-names><![CDATA[S.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Shear]]></surname>
<given-names><![CDATA[N.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sulfonamide hypersensitivity: Fact and fiction]]></article-title>
<source><![CDATA[J. Allergy Clin. Immunol. Pract]]></source>
<year>2019</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2116-23</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labbé]]></surname>
<given-names><![CDATA[J.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Peres]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Leclair]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Goulon]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Scemama]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Jourdel]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Duparc]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute osteomyelitis in children: the pathogenesis revisited?]]></article-title>
<source><![CDATA[Orthopaedics &amp; Traumatology: Surgery &amp; Research]]></source>
<year>2010</year>
<volume>96</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>268-75</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rea-Chauca]]></surname>
<given-names><![CDATA[D.R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores de riesgo de la osteomielitis en niños y adolescentes menores de 15 años atendidos en el Hospital Delfina Torres de Concha de la ciudad de Esmeraldas en el período junio 2014-abril 2015]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Guayaquil]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agúndez-Reigosa]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Molina-Amores]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Sentchordi-Montané]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Osteomielitis, Guía-ABE (v.1/2011), Infecciones en pediatría: guía rápida para la selección del tratamiento antimicrobiano empírico]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Straatmann]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bahia]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Pedral-Sampaio]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Brites]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[randomized]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients allergic to sulfonamides]]></article-title>
<source><![CDATA[Braz. J. Infect. Dis]]></source>
<year>2002</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>276-80</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castells-Guitart]]></surname>
<given-names><![CDATA[M.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century]]></article-title>
<source><![CDATA[J. Investing Allergol. Clin. Immunol]]></source>
<year>2014</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>72-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sancho]]></surname>
<given-names><![CDATA[M.d.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Breslow]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Sloane]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Castells]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensitization for hypersensitivity reactions to medications]]></article-title>
<source><![CDATA[Chem. Immunol. Allergy]]></source>
<year>2012</year>
<volume>97</volume>
<page-range>217-33</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huerta-López]]></surname>
<given-names><![CDATA[J.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Pedroza-Meléndez]]></surname>
<given-names><![CDATA[Á.]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas-Larrauri]]></surname>
<given-names><![CDATA[F.E.]]></given-names>
</name>
<name>
<surname><![CDATA[López-Valentín]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alergia a trimetoprim con sulfametoxazol en pacientes con VIH esquemas de sensibilización en el Instituto Nacional de Pediatría. Reporte de 2 casos]]></article-title>
<source><![CDATA[Alergia, Asma e Inmunología Pediátricas]]></source>
<year>2007</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>81-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caumes]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value of desensitization for reintroducing trimethoprim-sulfa-methoxazole in hypersensitive patients with HIV infection]]></article-title>
<source><![CDATA[Ann. Med. Interne]]></source>
<year>1997</year>
<volume>148</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>172-6</page-range><publisher-loc><![CDATA[Paris ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caumes]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Guermonprez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Winter]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Katlama]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Bricaire]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus]]></article-title>
<source><![CDATA[Clin. Infect. Dis]]></source>
<year>1996</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1313-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Madalon]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wortham]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Graziano]]></surname>
<given-names><![CDATA[F.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literature]]></article-title>
<source><![CDATA[WMJ]]></source>
<year>1998</year>
<volume>97</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>23-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonfanti]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Pusterla]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Parazzini]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Libanore]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cagni]]></surname>
<given-names><![CDATA[A.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Franzetti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Faggion]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Landonio]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Quirino]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[C.I.S.A.I. Group The effectiveness of desen-sitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study]]></article-title>
<source><![CDATA[Biomed. Phar-macother]]></source>
<year>2000</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Rieder]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole]]></article-title>
<source><![CDATA[Cochrane Database Syst. Rev]]></source>
<year>2007</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>CD005646</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pujal-Herranz]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Roca-Massa]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Tordera]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Codina-Jané]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas-Sala]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensibilizacion de cotrimoxazol, rifampicina y penicilina G sódica en nueve pacientes con hipersensibilidad previa]]></article-title>
<source><![CDATA[Farm. Hosp.]]></source>
<year>2006</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>254-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benaye]]></surname>
<given-names><![CDATA[J. El]]></given-names>
</name>
<name>
<surname><![CDATA[Nihal]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Hicham]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sept heures pour une désensibilisation efficace et sans risque chez les patients VIH positifs intolérants au cotrimoxazole]]></article-title>
<source><![CDATA[Pan. Afr. Med. J.]]></source>
<year>2014</year>
<volume>18</volume>
<page-range>238</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patriarca]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Schiavino]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Buonomo]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Aruanno]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Altomonte]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Nucera]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensitization to co-trimoxazole in a patient with fixed drug eruption]]></article-title>
<source><![CDATA[J. Investig. Allergol. Clin. Immunol]]></source>
<year>2008</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>309-11</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Firmino-Pereira]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Vivolo-Aun]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Portilho-Kelmann]]></surname>
<given-names><![CDATA[N.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Abílio-Motta]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Giavina-Bianchi]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loss of tolerance 5 days after discontinuing sulphonamide introduced via desensitization in delayed reaction]]></article-title>
<source><![CDATA[Einstein]]></source>
<year>2019</year>
<volume>18</volume>
<publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
